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Abstract
Background: There is limited evidence on whether screening for type 2 diabetes mellitus affects health outcomes.
A recent systematic review of randomised clinical trials found only one trial that met their inclusion criteria;
therefore, current guidelines for screening interventions for type 2 diabetes mellitus are based on expert opinions
and best practice rather than synthesised evidence. This systematic review seeks to collate evidence from non-
randomised studies to investigate the effect of screening for adults with type 2 diabetes on outcomes including
diabetes-related morbidity, mortality (all-cause and diabetes-related) and harms.
Methods: This systematic review will follow Effective Practice and Organisation of Care (EPOC) guidelines for the
synthesis of non-randomised studies. We will search PubMed/MEDLINE, Scopus, Web of Science, CINAHL, Academic
Search Premier and Health Source Nursing Academic (from inception onwards). We will include non-randomised
trials, controlled before-after studies, interrupted time-series studies, repeated measures studies and concurrently
controlled prospective cohort studies. The primary outcome will be diabetes-related morbidity (microvascular
complications of diabetic retinopathy, nephropathy or neuropathy or macrovascular complications of non-fatal
myocardial infarction, peripheral arterial disease or non-fatal stroke). The secondary outcomes will be mortality (all-
cause and diabetes-related) and harms of screening strategies to patients (including psychological harms or adverse
events following treatments) or to health care system (including resource allocation for false-positives or
overdiagnosis). Two reviewers will independently screen all citations and full-text articles. Data will be abstracted by
one reviewer and checked by a second. The risk of bias of individual studies will be appraised using the ROBINS-I
tool. GRADE will be used to determine the quality of the scientific evidence. If feasible, we will conduct random
effects meta-analysis where appropriate. If necessary, analyses will be conducted to explore the potential sources of
heterogeneity (e.g. age, sex, socio-economic status, rural versus urban or low-middle income versus high-income
country). We will disseminate the findings via publications and through relevant networks.
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Discussion: The protocol outlines the methods for systematically reviewing and synthesising evidence of screening
strategies for type 2 diabetes mellitus and their effect on health outcomes associated with the disease. The
potential impact of this systematic review is improved evidence-informed decision-making for policies and practice
for screening of type-2 diabetes.
Systematic review registration: PROSPERO CRD42020147439
Keywords: Screening, Mass screening, Targeted, Opportunistic, Type 2 diabetes mellitus
Background
Description of the condition
Diabetes mellitus is a disease of increasing global con-
cern. The global prevalence of diabetes was approxi-
mately 425 million people in 2017, approximately 8.5%
of the adult population, and is expected to double by
2045 [1]. In high-income countries, type 2 diabetes mel-
litus accounts for approximately 90% of diabetes cases;
there is insufficient data to estimate the ratio of type 2
diabetes mellitus in low- and middle- income countries,
but it is assumed to be similar [1, 2]. Clinical diabetes is
diagnosed through the detection of elevated levels of
glucose in the blood (hyperglycemia) [3]; however, it is
estimated that half of the people who have diabetes are
not diagnosed [1].
In addition to those individuals who have clinical dia-
betes, another 352 million, approximately 7.3% of the
adult population, have intermediate blood glucose levels
that are considered in between normal and clinically
diagnosed diabetes [1, 3]. These intermediate blood
glucose levels perform as a risk score, where increasing
values are associated with an increasing likelihood of
progression to diabetes, cardiovascular disease and all-
cause mortality [2, 4]. Patients who present with
intermediate levels of blood glucose are described using
a number of terminologies including mild glucose
intolerance, non-diabetic hyperglycaemia and prediabe-
tes. The terminology promoted by the World Health
Organization (WHO) is impaired glucose tolerance
(IGT), impaired fasting glucose (IFG) and intermediate
hyperglycaemia [3, 5]. The term prediabetes is gaining in
popularity even though the WHO has warned its use
may lead to disease stigma and detract from the signifi-
cant cardiovascular risk of this population [5]. About a
third of people with IGT and IFG are young, aged be-
tween 20–39 years, meaning they will spend many years
at risk of developing diabetes [1]. Other risk factors,
apart from intermediate glucose levels, for the develop-
ment of diabetes are increasing age of more than 45
years and obesity [2].
Type 2 diabetes mellitus arises due to defective insulin
activity in body tissues, defective insulin secretion from
pancreas or a combination of the two [2]. Type 2
diabetes mellitus usually occurs in older adults, but with
a change in lifestyle factors, such as inactivity and obes-
ity, the condition is increasingly being detected in chil-
dren, adolescents and young adults [1, 2]. Current
management of type 2 diabetes mellitus involves lifestyle
modification: increasing physical activity, improving diet,
reaching a healthy body weight and stopping smoking,
all monitored by regular screening [2]. If lifestyle modifi-
cation does not result in sufficiently decreased blood
glucose levels, medication may be prescribed, of which
there are a range of treatment options available [2]. The
complication with type 2 diabetes mellitus is the long la-
tency period, often lasting several years, during which
time the individual is often asymptomatic and unaware
of their condition [1, 2]. This prolonged asymptomatic
state results in long-term damage to the body’s organs
that leads to negative health outcomes including preg-
nancy complications, oral health problems, disabilities
such as blindness, reduced wound healing, foot disease
that may require amputation, stroke, heart and kidney
disease and death [1–3].
Description of the intervention
There are many types of screening interventions and
strategies that may be used to detect disease in a popula-
tion often classified as mass, opportunistic and targeted
strategies—as presented in Table 1 [2, 6]. This system-
atic review will use these classifications, but if additional
strategies are noted, these too will be included.
The biochemical tests commonly used are fasting
plasma glucose (FPG), oral glucose tolerance test
(OGTT) and detection of glycated haemoglobin A1C
(HbA1c) although there are also urine glucose tests
available or random blood glucose tests [2, 6]. In
addition, there are a number of risk scores [7, 8], includ-
ing the Finnish Diabetes Risk Score (FINDRISC) [9] and
the American Diabetes Association’s risk test [10]; how-
ever, these are not commonly used as stand-alone
screening tools. Classification of patients post testing
can be termed as in the normal range or as having dia-
betes, impaired glucose tolerance (IGT) or impaired fast-
ing glucose (IFG) (as presented in Table 2) [1, 3].
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How the intervention might work
The theory behind screening for type 2 diabetes mellitus
is to identify either disease or associated risk factors to
initiate preventative measures that can halt, slow or im-
prove the course of disease [11]. Therefore, the earlier
the disease is detected, especially where there is high risk
of disease, theoretically, the better the expected out-
comes. The logic model in Fig. 1 describes a complex
system in which the intervention interacts with partici-
pants, context, implementation and how these affect the
outcomes and the impact of this research [12].
Why it is important to do this review
Guidelines for screening interventions for type 2 dia-
betes mellitus, such as those released by the UK Na-
tional Screening Committee [13], the American Diabetes
Association [2] or the Society for Endocrinology, Metab-
olism and Diabetes of South Africa [14], are based on
expert opinion and local practice rather than synthesised
evidence. This is because there is limited information to
provide evidence about best practice for screening inter-
ventions for type 2 diabetes mellitus and even less evi-
dence in low- and middle-income countries [15]. A
recently published Cochrane review assessed the effects
of any type of screening compared with no screening for
type 2 diabetes [16] and found only one trial, the ADDI
TION-Cambridge trial [17], that met their inclusion
criteria. The ADDITION-Cambridge trial consisted of
20,184 participants aged 40–69 years from general prac-
tices in England who were at risk for diabetes but had
no known diabetes. These participants were randomised
to screening versus no screening arms, and followed up
for a median of 9.6 years (November 2001 to November
2011). The review found moderate certainty evidence
that screening for diabetes probably makes little or no
difference to all-cause mortality and low certainty evi-
dence that it may make little or no difference to
diabetes-related mortality. However, because the review
only included one trial, firm conclusions about early dia-
betes screening on health outcomes cannot be drawn. In
consultation with the authors of the unpublished
Cochrane review and considering the public health im-
portance of screening and the potential impact on large
populations, we propose to assess evidence from non-
randomised intervention study designs. The questions
for the systematic review will include the following: Does
screening for type 2 diabetes mellitus reduce morbidity
and/or mortality? Does a particular screening strategy
result in a greater reduction of morbidity and/or mortal-
ity as compared to another screening strategy? Does
screening for type 2 diabetes mellitus result in harms to
participants or the health system?
Objectives
Primary objective
To assess the effectiveness of targeted, opportunistic or
mass screening for type 2 diabetes mellitus on reduction
of diabetes-associated morbidity in adults
Secondary objectives
To assess the effectiveness of targeted, opportunistic or
mass screening for type 2 diabetes mellitus on reduction
of mortality (all cause as well as diabetes-associated) in
adults
To assess the harms of targeted, opportunistic or mass
screening for type 2 diabetes mellitus in adults
Methods
The present protocol has been registered within the
PROSPERO database (CRD42020147439). This manu-
script is being reported in accordance with the reporting
guidance provided in the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses Protocols (PRIS
MA-P) statement [18] (see checklist in Additional file 1).
Table 1 Screening strategies applied to detect diabetes
Mass Screening of an entire apparently healthy population regardless of risk factors
Opportunistic Screening of individuals, who may or may not be considered at-risk for diabetes, when presenting for any reason to the health system
or other opportunistic interaction (e.g. HIV testing drive)
Targeted Seeking out and screening individuals from a population who are considered at-risk of developing diabetes (e.g. obese, older age)
Table 2 WHO recommended ranges used to classify patients




≥ 7.0 mmol/L (126 mg/dl) OR
2-h plasma
glucose*
≥ 11.1 mmol/L (200mg/dl) OR
HbA1c ≥ 6.5%
Impaired glucose tolerance (IGT)
Fasting plasma
glucose
< 7.0 mmol/L (126mg/dl) AND
2-h plasma
glucose*
≥ 7.8 and < 11.1 mmol/L (140 mg/dl and 200mg/
dl)
Impaired fasting glucose (IFG)
Fasting plasma
glucose




< 7.8 mmol/L (140mg/dl)
*Venous plasma glucose 2 h after ingestion of 75 g oral glucose load
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Study and source eligibility
Types of studies
As existing reviews have found limited randomised evi-
dence addressing this question [15, 19, 20], we will focus
on non-randomised intervention studies (NRIS). We will
employ the Cochrane EPOC criteria [21], and NRIS of
interest will include non-randomised trials, controlled
before-after studies, interrupted time-series study, re-
peated measures study and concurrently controlled pro-
spective cohort study. The difficulty associated with
labelling NRIS is well-documented in the literature; sev-
eral of these designs, for example, have been used inter-
changeably; we will make use of the EPOC definitions
and flow diagram to assist in study design identification
(Appendix 1):
 Non-randomised trial (NRT) is a study design in
which individual participants, or clusters of
participants, are allocated to intervention or
comparator in a quasi-random or non-random man-
ner. If there is an allocation rule, it is often by, for
example, alternation, day of the week, odd/even hos-
pital, or identification number.
 Controlled before-after (CBA) is a study design that
estimates intervention effectiveness by comparing
pre- and post-intervention outcomes in individuals
or clusters that receive the intervention and those
that do not.
 Interrupted time series (ITS) studies design uses
multiple observations from individuals or
clusters pre-intervention to establish the pre-
existing outcome trend; intervention effective-
ness is then estimated by measuring post-
intervention changes in the expected outcome
trend associated with the introduction of an
intervention (the ‘interruption’). An ITS study
can identify both immediate and long-term
changes associated with the intervention. The
interrupted time-series studies will be required
to have a clearly defined point in time when the
intervention occurred and a minimum of 3 time
points before and 3 time points after the inter-
vention [21].
 A repeated measures (RM) study is an interrupted
time-series study but where the outcomes of interest
are measured in the same participants at each point
in time.
 Concurrently controlled prospective cohort study
(PCS) is where subjects are identified
prospectively as having received an intervention
or comparator and are then followed over time.
The allocation rule is often in relation to
organizational factors such as ward, clinic, doctor
or provider organisation. Control arms should be
contemporaneous, we will not include
retrospective control arms.
Fig. 1 Logic model describing the interactions between screening for diabetes, implementation, context, participants, outcomes and impact
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‘PICO’ eligibility
Types of participants
We will include adults aged 18 years and older without
documented diabetes mellitus or pregnancy.
Types of interventions
We will include studies comparing one of the screening
strategies, targeted, opportunistic or mass screening in-
terventions for the detection of type 2 diabetes mellitus,
against no screening or another of the screening strat-
egies (Table 1). There will be a 6-month minimum
follow-up time required for the primary clinical outcome
of morbidity.
Types of outcome measures
Primary outcomes Clinical outcomes
 Diabetes-related morbidity defined as study-reported
microvascular complications (diabetic retinopathy,
diabetic nephropathy, diabetic neuropathy) or
macrovascular complications (non-fatal myocardial
infarction, peripheral arterial disease, non-fatal
stroke) and measured from 6months after screening
Secondary outcomes Clinical outcomes
 Mortality (all-cause and diabetes-related) defined as
death due to any-cause including diabetes or other
cardiovascular causes (including acute myocardial
infarction, ischemic heart disease, stroke or any car-
diovascular disorder that lead to death) and mea-
sured at any time after screening
Harms of diabetes screening
Harms to patients is defined as event/s reported in the
study at any time after screening.
 Psychological harms such as anxiety or stigma that
impacts on quality of life due to a false-positive test
 Number of days of work lost
 Side-effects from treatment
 Loss of health insurance benefits
Harms to health care system is defined as event/s re-
ported in the study at any time after screening.
 False-positive test resulting in human, physical and
financial resource allocation to patients who are not
in need
 Overdiagnosis may lead to over-extension of human,
physical and financial resources for patients who
end up in prolonged treatment and engagement with
the health system even if they never develop disease
The rationale for prioritisation of outcomes: Primary
outcome serves to inform whether screening alters the
course of disease as assumed per screening theory [11]
and depicted in Fig. 1. Secondary outcome of mortality
contributes to the current data outlining no reduction in
mortality following screening intervention [19] while
also assessing harms that may arise from screening inter-
vention [3] and therefore contribute to evidence to sub-
stantiate policy and practice recommendations.
Search methods for identification of studies
Electronic searches
The University of Cape Town Health Sciences Reference
Librarian (MS) assisted the first author (HM) in develop-
ing the search strategy and will provide advice and guid-
ance in conducting the searches for the review.
Electronic Database Search (from inception onwards)
 PubMed (MEDLINE)
 Scopus (includes majority of EMBASE contents)
 Web of Science Platform (Web of Science Core
Collection, Biological Abstracts, SciELO Citation
Index)
 Academic Search Premier (on the EBSCOhost
platform)
 CINAHL (on the EBSCOhost platform)
 Health Source Nursing Academic (on the
EBSCOhost platform)
A draft search strategy for PubMed/MEDLINE, based
on the original search strategy utilised by the Cochrane
Review team and revised by an information specialist, is
provided in Appendix 2 (see Appendix 2). We will in-
clude all studies regardless of publication status; how-
ever, we will only include English language studies. We
are aware that this decision may lead to language bias
[22], but due to capacity and resource limitation of the
systematic review team, we are restricted to English only.
We will search all databases from inception to the date
of search. The search syntax will first be tested and opti-
mised in PubMed. We will thereafter replicate the
searches in the other databases adapting search syntax
as necessary for those databases.
Grey literature search We will conduct a grey literature
search to identify studies not indexed in the databases
listed above.
 OpenGrey (multidisciplinary European database,
covering science, technology, biomedical science,
economics, social science and humanities)
 Conference abstracts from The American Diabetes
Association (ADA), the European Association for
the Study of Diabetes (EASD) meeting and
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Diabetologia will be used to track down full text
articles.
 National Institute for Health Research Economic
Evaluation Database (NHS EED)
 Cost-Effectiveness Analysis Registry (CEA)
(www.healtheconomics)
We will search key references, such as systematic re-
views, by cross-checking reference lists for additional po-
tentially eligible primary studies [23]. We will also
contact experts in the field to check if we have missed
any relevant studies. We may contact authors of in-
cluded studies to clarify reported published information
and to seek unpublished data.
Methods for screening search results
Screening methods
We will collate and transfer search results to the Rayyan
screening software [24] and remove duplicate records.
At least two review authors will independently screen ti-
tles and abstracts of every record retrieved. Outcome
measures will not be used to exclude studies during title
and abstract screening. The potentially eligible records
will be retrieved for full text screening. The two review
authors will independently review full text records for
compliance of studies with eligibility criteria of the re-
view. A decision tree based on the eligibility criteria will
be used to assist in decision making for exclusion of
studies (see Appendix 3). Two review authors will re-
solve any disagreements through discussion or, if re-
quired, will consult a third review author. A study
must meet all inclusion criteria to be included. We
will list excluded studies at the full text screening
stage in the ‘Characteristics of excluded studies’ table.
We will collate multiple reports of the same study so
that each study rather than each report is the unit of
interest in the review. We will provide any informa-
tion we can obtain about ongoing studies. We will
record the selection process in sufficient detail to
complete a PRISMA flow diagram [25].
Data collection and analysis
Data extraction
We will use a standard data extraction form in Microsoft
Excel to capture study characteristics and outcome data
[22, 26]; we will pilot the form on at least one eligible
study. One review author will extract the following study
characteristics from the included studies, and an inde-
pendent review author will check the extraction:
1. Source: study ID (created by review author), review
author ID (created by review author), citation and
contact details
2. Eligibility: confirm eligibility for review, reason for
exclusion
3. Methods: study design, number of study centres
and location, study setting, withdrawals, date of
study, follow-up, confounding factors considered,
and the methods used to control for confounding,
aspects of risk of bias specific for NRIS (see “Assess-
ment of risk of bias in included studies” below),
how missing data was handled
4. Participants: number, mean/median age, age range,
gender, severity of condition, diagnostic criteria,
inclusion criteria, exclusion criteria, screening
criteria, diagnostic criteria, presence of known risk
factors for type 2 diabetes mellitus (obesity, family
history), co-morbidity (hypertension, dyslipidaemia),
socio-demographics
5. Interventions: intervention components,
comparison, fidelity assessment using the Template
for Intervention Description and Replication
(TIDieR) as a guide [27]
6. Outcomes: primary and secondary outcomes
specified above in the section “Types of outcome
measures”.
7. Miscellaneous: funding source, notable conflicts of
interest of study authors, ethical approval, key
conclusions of the study authors, miscellaneous
comments from the study authors, references to
other relevant studies, correspondence required,
miscellaneous comments by the review authors.
One review author will extract outcome data from in-
cluded studies, and an independent review author will
check extracted data. We will note in the ‘Characteristics
of included studies’ table if outcome data were reported
in an unusable way. We will resolve disagreements by
consensus or by involving a third review author.
Assessment of risk of bias in included studies
Two review authors will independently assess risk of bias
for each study using the ROBINS-I tool [28]. Any dis-
agreement will be resolved by discussion or by involving
a third review author.
We will assess the risk of bias according to the follow-
ing domains:
1. Pre-intervention: bias due to confounding
2. Pre-intervention: bias in selection of participants
into the study
3. At intervention: bias in classification of
interventions
4. Post-intervention: bias due to deviations from
intended interventions
5. Post-intervention: bias due to missing data
6. Post-intervention: bias in measurement of outcomes
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7. Post-intervention: bias in selection of the reported
result
We will judge each potential source of bias as low risk,
moderate risk, serious risk, critical risk of bias or no in-
formation. We will summarise the ‘Risk of bias’ judge-
ments across different studies for each of the domains
listed. We will consider blinding separately for different
key outcomes where necessary (e.g. for unblinded out-
come assessment, risk of bias for all-cause mortality may
be very different than for a patient reported pain scale).
Where information on risk of bias relates to unpublished
data or correspondence with a trialist, we will note this
in the ‘Risk of bias’ table. We will not exclude studies on
the grounds of their risk of bias but will clearly report
the risk of bias when presenting the results of the stud-
ies. When considering treatment effects, we will take
into account the risk of bias for the studies that contrib-
ute to that outcome. We will conduct the review accord-
ing to this published protocol and report any deviations
from it in the ‘Differences between protocol and review’
section of the systematic review.
Dealing with missing data
Authors will be contacted, and missing data will be re-
quested. If only returned in part and data can be logic-
ally imputed, such as standard errors, this will occur. All
missing data will be clearly reported in the data extrac-
tion forms and risk of bias table and as such be assessed
in the sensitivity analysis.
Data management
EndNote X9 and Microsoft Excel will be used for data
management. If there is a conflict between data reported
across multiple sources for a single study (e.g. between a
published article and a trial registry record), we will re-
port the data from the first peer-reviewed published
article.
Data synthesis
Preparation for data synthesis
In preparation for synthesis (either meta-analyses or syn-
thesis without meta-analysis), we will assess how much
data are available for each of our objectives by creating a
table to compare the PICO elements and the study de-
sign features as well as the extracted numerical data for
the compilation of a meta-analysis.
Measures of treatment effect
We will estimate the effect of the intervention using risk
ratio for dichotomous data, and mean difference or stan-
dardised mean difference for continuous data. Time to
event outcomes will be reported as hazard ratios. If
other effect estimates are provided, we will convert
between estimates where possible. Measures of precision
will be 95% confidence intervals. We will ensure that an
increase in scores for continuous outcomes can be inter-
preted in the same way for each outcome, explain the
direction to the reader, and report where the directions
were reversed if this was necessary. Interrupted time
series data will be analysed and, if required, a statistical
comparison of time trends before and after the interven-
tion will be performed. For ITS studies, the guideline as
outlined in Analysis in EPOC reviews will be followed
with assistance of a statistician to ensure integrity of
analysis [29].
Unit of analysis issues
To avoid unit of analysis errors we will consider the unit
used to cluster the intervention (such as a ward, clinic,
doctor or provider organisation) or in the case of re-
peated measures that there will be multiple observations
for the same outcome. For instance, multiple screening
intervention events per participant may occur over time
that may cause a unit-of-analysis error. In order to cal-
culate the confidence intervals, the participants per
treatment group rather than the number of intervention
attempts will be used [22]. Multiple intervention groups
could create unit-of-analysis issues especially if different
screening interventions are compared against no screen-
ing intervention and use the same participants with no
screening intervention in both comparisons [22]. If there
is more than one comparison in the study design, we
will combine groups into a single pairwise comparison.
If there is a unit of analysis error in the reported analysis
for a study and there is insufficient information to reana-
lyse the results, the study authors will be contacted to
obtain necessary data. If these data are not available, we
will not report confidence intervals or p values for which
there is a unit of analysis error [30].
Quantitative synthesis
We will undertake meta-analyses only where this is
meaningful, i.e. if the interventions, participants and the
underlying clinical question are similar enough for pool-
ing to make sense. If feasible and appropriate, outcome
data from primary studies will be used to perform ran-
dom effects meta-analyses. Since heterogeneity is ex-
pected a priori, we will estimate the pooled treatment
effect estimates and its 95% confidence interval using
the random effects model. The random effects model as-
sumes that the effect estimates follow a normal distribu-
tion, considering both within-study and between-study
variation.
Assessment of heterogeneity
Forest plots will be used to visualise the extent of het-
erogeneity among studies. We will quantify statistical
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heterogeneity by estimating the variance between studies
using I2 statistic. The I2 is the proportion of variation in
effect estimates that is due to genuine variation rather
than sampling (random) error. I2 ranges between 0 and
100% (with values of 0–25% and 75–100% taken to indi-
cate low and considerable heterogeneity, respectively)
[22]. We will also calculate the chi-squared test where a
p value < 0.1 indicates statistically significant
heterogeneity.
Assessment of publication bias
If we include more than 10 studies investigating a par-
ticular outcome, we will use a funnel plot to explore
possible publication bias, interpreting the results with
caution [31].
Subgroup analysis and investigation of heterogeneity
We expect the following population characteristics may
introduce clinical heterogeneity: age, sex, socio-
economic status [6].
We expect the following contexts may introduce
health system heterogeneity: study setting of rural or
urban or in a low-middle income country or a high-
income country (as defined by the World Bank) [6].
We will use the following outcomes in subgroup
analysis:
1. Diabetes-associated morbidity
2. Mortality (all-cause and diabetes-associated)
3. Harms
Sensitivity analysis
We may conduct a sensitivity analysis to explore the in-
fluence of various factors on the effect size of the pri-
mary outcomes of the review only. We will stratify
studies according to:
1. Restricting the analysis to published studies.
2. Restricting the analysis to studies with a low risk of
bias, as specified in “Assessment of risk of bias in
included studies”
3. Imputing missing data.
Any post hoc sensitivity analyses that may arise during
the review process will be justified in the final report.
Assessment of certainty of evidence using the GRADE
approach
Two review authors will independently assess the
certainty of the evidence (high, moderate, low and
very low) for each outcome using the five GRADE
considerations for downgrading the certainty of evi-
dence (risk of bias, consistency of effect, imprecision,
indirectness, and publication bias) and the three
criteria for upgrading the certainty of evidence (large
effect, dose response and residual confounding op-
posing the observed effect) [32]. We will use the
GRADEpro software GDT [33] to create the ‘Sum-
mary of findings’ tables for the main intervention
comparisons and include the following outcomes:
diabetes-associated morbidity, mortality (all-cause
and diabetes-associated), harms (see Appendix 4 for
SoF). We will resolve disagreements on certainty rat-
ings by discussion and provide justification for deci-
sions to down- or upgrade the ratings using
footnotes in the SoF table and make comments to
aid readers’ understanding of the review where ne-
cessary. We will use plain language statements to re-
port these findings in the review [34]. The SoF
tables will be used to draw conclusions about the
certainty of the evidence within the text of the re-
view. If during the review process, we become aware
of an important outcome that we failed to list in our
planned ‘SoF’ tables, we will include the relevant
outcome and explain the reasons for this is the sec-
tion ‘Differences between protocol and review’.
Discussion
Systematic reviews of screening for type 2 diabetes have
found no evidence that this intervention saves lives [15,
19, 20]; therefore, this review will primarily focus on the
impact of screening on the reduction of diabetes-
associated morbidities. The impact of this review is syn-
thesised data for the provision of evidence-based
decision-making for informing policy and practice
around screening strategies for type 2 diabetes mellitus.
Important protocol amendments will be documented
and noted in the discussion.
Limitations
The potential limitations of this review at a study
(outcome) level include the following: the potential
finding of insufficient studies of similar study design
and clinical question to synthesise abstracted study
data; the overall completeness and applicability of
evidence and quality of evidence especially due to
the limitation to non-randomised studies due to the
lack of randomised studies and therefore the lower
quality of evidence; the limitation to English studies
only and therefore the potential to miss published
research; the limitation of not being able to discern
between all-cause mortality and diabetes-related
mortality and therefore combining this outcome
under one mortality outcome. The potential limita-
tion of this review at a systematic review process
level includes the potential biases in the review
process such as post hoc analysis and focus of out-
come objectives.
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Appendix 2
Search Strategy for PubMed:
Set 1: Diabetes Mellitus, Type 2 [MeSH] OR [Text Word
field:] Adult onset diabetes OR late onset diabetes OR
latent diabetes OR mature onset diabetes OR MODY
OR NIDDM OR noninsulin-dependent diabetes OR slow
onset diabetes OR stable onset diabetes OR type 2 dia-
betes OR type II diabetes OR T2DM OR T2D
Set 2: Diabetes Insipidus [MeSH] OR [Text Word
field:] diabetes insipidus
Set 3: 1 NOT 2
Set 4: Mass screening [MeSH] OR [Text Word field:]
screening
Set 5: 3 AND 4
Set 6: Animals [MeSH] NOT Humans [MeSH]
Set 7: 5 NOT 6
Set 8: [All fields:] Trial OR trials OR before-and-
after study OR before-and-after studies OR cohort
OR comparative study OR comparative studies OR
Controlled OR evaluation study OR evaluation stud-
ies OR follow-up study OR follow-up studies OR
interrupted time series OR longitudinal study OR
longitudinal studies OR non-randomised OR non-
randomized OR nonrandomised OR nonrandomized
OR non randomised OR non randomized OR
program evaluation OR programme evaluation OR
prospective study OR prospective studies OR quanti-
tative study OR quantitative studies OR quasi experi-
mental OR repeated measures
Set 9: 7 AND 8
Appendix 1
Fig. 2 Flow diagram to assist with identifying the type of study (modified from [34])
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Appendix 3
Table 3 Provisional eligibility decision tree for full text exclusion
Hierarchy Exclusion reason Explanation of reason
1 Duplicate Record is a duplicate of another study already included in the review
2 Animal study Study conducted in non-human population
3 Study withdrawn Study was withdrawn before results became available
4 Ongoing study Study is ongoing; No study results have been published. Study will be described in ‘Ongoing studies’
section of the review.
5 Wrong intervention Study does not include screening for type 2 diabetes mellitus
6 Wrong study design Study is not eligible as per Appendix 1 study designs.
7 Wrong population Study intervention/ outcomes involve individuals who have type 2 diabetes mellitus or are pregnant
8 Research question is
inappropriate
Study is not eligible due to inappropriate research question or objectives that do not address systematic
review objectives.
9 Wrong Outcomes Study does not report outcomes that align with primary or secondary outcome measures.
Appendix 4
Table 4 Provisional summary of findings table
Targeted, opportunistic or mass screening for type 2 diabetes mellitus compared to each other or no screening in children, adolescents and adults.
Patients or population Children, adolescents and adults without documented diabetes mellitus or pregnancy.
Intervention Targeted, opportunistic or mass screening for type 2 diabetes mellitus.
Comparison Other screening (targeted, opportunistic or mass) or no screening for type 2 diabetes mellitus.










Assumed risk Corresponding risk
With targeted, opportunistic
or mass screening
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